Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on April 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure). $25M term loan fully drawn to help finance Corstasis acquisition.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $25M term loan fully drawn to help finance Corstasis acquisition
- Loan repayment before April 2, 2028 triggers make-whole interest plus 3% premium
- Repayment premiums decline to 3% through April 2, 2029 and 1% through April 2, 2030
- $50M upfront royalty monetization from Otsuka Territory receivables
- Purchaser receives 100% of receivables until collecting $100M, after which royalties revert to Esperion
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Esperion completed Corstasis Therapeutics’ merger on April 2, 2026, making Corstasis a wholly owned subsidiary
- $75 million cash upfront consideration, subject to customary and post-closing adjustments
- Additional milestone payments up to $180 million tied to regulatory approvals and commercial sales
- Future royalty and licensing-revenue payments create additional contingent acquisition costs linked to product sales
Item 7.01 · Regulation FD Disclosure
- April 2, 2026 press release announced closing of the Merger
- Amendment executed alongside the Merger closing, indicating modified transaction terms
- Royalty Purchase Agreement entered, creating a separate royalty-related transaction
- Exhibit 99.1 contains the substantive deal details investors need for valuation and obligations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.